Nuravax develops and researches on vaccines, preventive solutions and treatment for neurodegenerative disorders.
Nuravax has raised $3.0M in total funding. The most recent round was Grant. The last funding was announced in May 2025.
Nuravax's investors include National Institutes of Health.
Nuravax is headquartered in Irvine, United States.
Nuravax develops and researches on vaccines, preventive solutions and treatment for neurodegenerative disorders.
Nuravax is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nuravax — Funding & Investors." VCBacked, May 5, 2025, https://www.vcbacked.co/company/nuravax. Accessed July 19, 2026.
VCBacked. (2025). Nuravax — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/nuravax
{{cite web |title=Nuravax — Funding & Investors |url=https://www.vcbacked.co/company/nuravax |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated